Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
- PMID: 36161051
- PMCID: PMC9372809
- DOI: 10.3748/wjg.v28.i28.3535
Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios
Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer worldwide. Viral hepatitis is a significant risk factor for HCC, although metabolic syndrome and diabetes are more frequently associated with the HCC. With increasing prevalence, there is expected to be > 1 million cases annually by 2025. Therefore, there is an urgent need to establish potential therapeutic targets to cure this disease. Peroxisome-proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor that plays a crucial role in the patho-physiology of HCC. Many synthetic agonists of PPARγ suppress HCC in experimental studies and clinical trials. These synthetic agonists have shown promising results by inducing cell cycle arrest and apoptosis in HCC cells and preventing the invasion and metastasis of HCC. However, some synthetic agonists also pose severe side effects in addition to their therapeutic efficacy. Thus natural PPARγ agonists can be an alternative to exploit this potential target for HCC treatment. In this review, the regulatory role of PPARγ in the pathogenesis of HCC is elucidated. Furthermore, the experimental and clinical scenario of both synthetic and natural PPARγ agonists against HCC is discussed. Most of the available literature advocates PPARγ as a potential therapeutic target for the treatment of HCC.
Keywords: Anticancer; Hepatocellular carcinoma; Natural agonists; Peroxisome proliferator-activated receptor-γ; Thiazolidinediones.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors have no conflict of interests to declare.
Figures
Similar articles
-
Peroxisome proliferator-activated receptor gamma expression along the male genital system and its role in male fertility.Hum Reprod. 2020 Sep 1;35(9):2072-2085. doi: 10.1093/humrep/deaa153. Hum Reprod. 2020. PMID: 32766764 Review.
-
Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma.J Hepatocell Carcinoma. 2014 Aug 26;1:127-35. doi: 10.2147/JHC.S48512. eCollection 2014. J Hepatocell Carcinoma. 2014. PMID: 27508182 Free PMC article. Review.
-
Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma.J Hepatobiliary Pancreat Sci. 2016 Sep;23(9):574-84. doi: 10.1002/jhbp.378. Epub 2016 Aug 16. J Hepatobiliary Pancreat Sci. 2016. PMID: 27451128
-
Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma.J Gastroenterol Hepatol. 2012 Nov;27(11):1665-9. doi: 10.1111/j.1440-1746.2012.07213.x. J Gastroenterol Hepatol. 2012. PMID: 22742931
-
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.Oncol Rep. 2007 Oct;18(4):825-32. Oncol Rep. 2007. PMID: 17786342
Cited by
-
Nano-revolution in hepatocellular carcinoma: A multidisciplinary odyssey - Are we there yet?World J Hepatol. 2024 May 27;16(5):684-687. doi: 10.4254/wjh.v16.i5.684. World J Hepatol. 2024. PMID: 38818296 Free PMC article.
-
Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives.Int J Mol Sci. 2024 Feb 28;25(5):2798. doi: 10.3390/ijms25052798. Int J Mol Sci. 2024. PMID: 38474047 Free PMC article. Review.
-
Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease-Oxidative Stress and Inflammation Relevance.Medicina (Kaunas). 2023 Sep 7;59(9):1614. doi: 10.3390/medicina59091614. Medicina (Kaunas). 2023. PMID: 37763733 Free PMC article. Review.
-
Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma.JHEP Rep. 2023 Jun 9;5(9):100811. doi: 10.1016/j.jhepr.2023.100811. eCollection 2023 Sep. JHEP Rep. 2023. PMID: 37575883 Free PMC article. Review.
-
Shikonin Binds and Represses PPARγ Activity by Releasing Coactivators and Modulating Histone Methylation Codes.Nutrients. 2023 Apr 6;15(7):1797. doi: 10.3390/nu15071797. Nutrients. 2023. PMID: 37049636 Free PMC article.
References
-
- Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci. 2019;64:910–917. - PubMed
-
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical